Lexaria Bioscience Corp. (NASDAQ: LEXX) Reports Positive Results From its Recent Animal Study on the Effectiveness of its DehydraTECH Drug Delivery Technology

  • Lexaria Bioscience Corp. announced positive results from its VIRAL-A20-2 study
  • This study showed strong gains in delivery of the DehydraTECH-enabled remdesivir and ebastine among animals
  • The success of this study shows the potential and commercial viability of Lexaria’s DehydraTECH

In June 2021, Lexaria Bioscience (NASDAQ: LEXX) announced positive results from its VIRAL-A20-2 study that evaluated the effectiveness of DehydraTECH-enabled remdesivir and ebastine among animals. The results were strongly positive and demonstrated greater effectiveness than in Lexaria’s first antiviral drug study reported in December 2000.

The research was a tolerability and pharmacokinetic (“PK”) study involving four groups of 10 animals each. It examined how they tolerated the DehydraTECH-enhanced drugs, looking for adverse effects as well as improvements in delivery of drugs into bloodstream. It evaluated peak concentration and total drug delivery into…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.